BioMendics
June 24, 2026
Theater 3
Type: Company Presentation
Focus Area:
Orphan and Rare Disease
BioMendics is a clinical-stage biotechnology company developing first-in-class therapies for rare genetic skin disorders characterized by protein aggregation, epithelial fragility, and chronic inflammation, including epidermolysis bullosa simplex (EBS). Its lead candidate, TolaSure® (BM-3103), is a novel non-rapalog topical small-molecule mTOR pathway modulator designed to address both pathogenic protein aggregation and inflammatory signaling.
In a Phase I/IIa study in Epidermolysis Bullosa Simplex (EBS), TolaSure demonstrated a 94% reduction in skin blistering, shortened flare duration, and restoration of keratin filament organization. The program has received Orphan Drug Designation and Rare Pediatric Disease Designation and is currently being evaluated in the Phase II TAMES-02 trial at Stanford University and Northwestern University.
BioMendics is seeking strategic partners and investors to advance its platform across EB and other monogenic keratin disorders.
Company HQ City:
Rootstown
Company HQ State:
Ohio
Company HQ Country:
United States
Year Founded:
2014
Lead Product in Development:
TolaSure 5% (w/w) topical gel for Epidermolysis Bullosa Simplex
CEO
Karen McGuire, PhD
Development Phase of Lead Product
Phase II
Number of Unlicensed Products Looking for Licensing
1
When you expect your next catalyst update?
Q4 2026
What is your next catalyst (value inflection) update?
Phase II clinical trial readout.
Primary Speaker
)
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}